CD47 and hematopoietic and lymphoid cell neoplasm: Clinical trials using anti-CD47 mAbs or CD47-Fc fusion proteins are on-going for the treatment of hematological cancers or refractory solid tumors in combination with anti-PD-1 therapy or with anti-CD20 (Rituximab®) to target B cells [159].